Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma

Jeong Hun Kim, Jin Hyoung Kim, Young Suk Yu, Dong Hun Kim, Bon Hong Min, Kyu Won Kim

    Research output: Contribution to journalArticlepeer-review

    23 Citations (Scopus)


    In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma. Here, we investigated whether arginine deprivation via arginine deiminase (ADI) could be a new anti-tumor therapy in retinoblastoma cells. Expression of argininosuccinate synthetase (ASS) was detected in human retinoblastoma tissues. Even with a high expression of ASS, ADI effectively inhibited the proliferation of retinoblastoma cells and induced retinoblastoma cell death in a dose-dependent manner. These results indicate that arginine deprivation via ADI could be another treatment option for retinoblastoma due to low ASS activity in retinoblastoma cells.

    Original languageEnglish
    Pages (from-to)1373-1377
    Number of pages5
    JournalOncology reports
    Issue number6
    Publication statusPublished - 2007 Dec


    • Arginine deiminase
    • Arginine deprivation
    • Argininosuccinate synthetase
    • Retinoblastoma

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma'. Together they form a unique fingerprint.

    Cite this